We already know that linking certain types of radioactive agent to specific forms of prostate-specific membrane antigen (PSMA) offers new opportunities for the treatment of challenging cases of prostate cancer. Research in this area has looked particularly promising with the combination of lutetium-177 and PSMAs. In a paper presented yesterday at the annual meeting of […]![]()
